HLF1-11, a human lactoferrin-derived peptide, is a broad spectrum antimicrobial agent. HLF1-11 inhibits human MPO activity. HLF1-11 also directs GM-CSF-driven monocyte differentiation toward macrophages, and enhances immune responses.
hLF1-11 (1, 10, and 100 μg/mL) directs differentiation of monocytes toward a macrophage subset during granulocyte-macrophage colony-stimulating factor (GM-CSF)-driven monocytes differentiation[2].hLF1-11 (0.5-250 μg/mL) inhibits human MPO activity[3].hLF1-11 (100 μg/mL, 90 min) inhibits ROS induction induced by LPS in monocytes[3].hLF1-11 (8-34 μΜ, 2 h) is active against fluconazole-resistant C. albicans[5].
hLF1-11 (20 mg/kg, injected into the debrided tibial cavity) shows ability against MRSA osteomyelitis in rabbits[4].hLF1-11 (40 μg/kg, i.v.) is active against C. albicans-infected mice[6].
References:
[1]. Marty Wulferink, et al. The Peptide hLF1-11 as Broad Spectrum Antmicrobial Proplaxis in HSCT Patients. Blood (2005) 106 (11): 3241. [2]. van der Does AM, et al. Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Chemother. 2010 Feb;54(2):811-6.
[3]. van der Does AM, et al. The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity. J Immunol. 2012 May 15;188(10):5012-9.
[4]. Faber C, et al. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staplococcus aureus osteomyelitis model. Antimicrob Agents Chemother. 2005 Jun;49(6):2438-44.
[5]. Lupetti A, et al. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother. 2000 Dec;44(12):3257-63.
[6]. upetti A, et al. Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. J Infect Dis. 2007 Nov 1;196(9):1416-24.